ProMIS Neurosciences, Inc.

What they do

ProMIS uses its in-licensed EpiSelect computational platform to identify conformational epitopes exposed only on misfolded, toxic forms of proteins, then generates humanized monoclonal antibodies against them. Its pipeline includes PMN310 for Alzheimer's disease, PMN267 for ALS, and PMN442 for synucleinopathies such as dementia with Lewy bodies and Parkinson's disease. The company is based in Toronto with a U.S. subsidiary in Delaware, and has traded on Nasdaq under PMN since its 2023 continuance into Ontario.

Revenue drivers

• PMN310 (Alzheimer's disease) — Lead product candidate, a monoclonal antibody targeting toxic amyloid-beta oligomers, currently in the Phase 1b PRECISE-AD trial; the company has no product revenue and depends on this program's success.
• PMN267 (ALS) — Second lead candidate designed to selectively recognize misfolded cytoplasmic TDP-43 aggregates; preclinical stage with no revenue contribution.
• PMN442 (synucleinopathies) — Third lead candidate showing preclinical binding to pathogenic alpha-synuclein oligomers and seeding fibrils; preclinical stage, no revenue.
• Platform licensing / partnering — EpiSelect platform is in-licensed from the University of British Columbia and could support future partnering or out-licensing, but no such revenue is reported.

Recent performance

For the six months ended June 30, 2026, ProMIS reported an operating loss of $20.9 million and negative operating cash flow of $22.8 million. As of June 30, 2026, the company had $53.4 million in cash and short-term investments, total assets of $56.7 million, total liabilities of $7.3 million, and an accumulated deficit of $150.4 million. In January 2026, ProMIS raised net proceeds of $70.1 million through a private placement of common shares and warrants to external investors and certain directors and management. Full-year 2025 net income was a loss of $39.7 million, or $22.61 per diluted share.

Strategy

ProMIS is focused on advancing PMN310 through the PRECISE-AD Phase 1b trial, which completed enrollment of 144 subjects in December 2025 and is expected to report unblinded 12-month topline data in the first quarter of 2027. The company expects its $53.4 million in cash to fund operations through 2027, beyond that topline readout. Management's stated thesis is that selectively targeting toxic amyloid-beta oligomers while avoiding plaque may offer a better safety profile, including reduced ARIA burden, and potential for improved efficacy. The company also maintains preclinical programs PMN267 and PMN442, but does not guide on their clinical timelines.

Risks

• Early-stage pipeline — All product candidates are in early development, and the 10-K states significant additional investment, manufacturing scale-up, and regulatory submissions are required before any commercialization.
• Going-concern / funding need — ProMIS has incurred significant operating losses since inception, had negative operating cash flow of $22.8 million in the first half of 2026, and expects to continue incurring losses for the foreseeable future.
• Reliance on a single lead asset — PMN310 is the only clinical-stage candidate, so any safety or efficacy setback in PRECISE-AD would materially affect the pipeline.
• Trial data uncertainty — The interim biomarker results were reported blinded and pooled across active and placebo patients, and management notes the trial remains blinded and ongoing, so efficacy cannot yet be assessed.

Outlook

Management expects all PRECISE-AD patients to complete 12-month dosing by the fourth quarter of 2026, with unblinded topline data including cognitive outcomes expected in the first quarter of 2027. ProMIS states its existing cash, including January 2026 proceeds, is sufficient to fund operating expenses and capital expenditure requirements through 2027. The company has not guided on timelines for PMN267 or PMN442 clinical development.